Browsing: Immunogenicity

Immunogenicity is the ability of a therapeutic protein to stimulate an immune response, developing antidrug antibodies to neutralize or bind the offending protein. It is an important assessment required for drug approvals that is measured and characterized. A key problem with protein-based therapeutics is their immunogenicity, which is the tendency to trigger an unwanted immune response. An important part of determining the efficacy and clinical safety of protein-based therapeutic products involves measuring their tendency to trigger the formation of antibodies.

The immunogenicity of therapeutic proteins is the result of the immune system doing its job —generating a response to a ‘foreign’ protein as a defensive mechanism to rapidly clear and/or neutralize the offending protein. From the perspective of patients, doctors and the pharmaceutical industry, this is an ‘unwanted’ immune response, as opposed to the desirable immune response elicited by an effective vaccine or by a pathogen and is typically manifested by the production of host antibodies directed against the protein therapeutic termed anti-drug antibodies (ADAs). This is what the use of ‘humanized’ or ‘fully human’ proteins are designed to avoid, what many bioanalytical scientists spend time and resources devising ways to measure and characterize, and what health authorities around the world scrutinize carefully in drug approval applications.

Assays for immunogenicity, measuring ADA against a protein therapeutic, are basically immunoassays that measure the ability of antibodies in a patient serum sample to bind to (and for neutralizing assays, neutralize) the drug. For non-mAb therapeutics a standard sandwich immunoassay is often used wherein the drug is immobilized either passively or via a linker such as biotin-drug to a streptavidin-coated microtiter plate. Plates are then incubated with serum samples, washed to remove nonbound proteins, and ADAs bound to the immobilized drug are detected.

For humanized or fully human mAb therapeutics using an anti-human Ig detector would detect the immobilized drug along with the ADA and is therefore not an effective format. Instead what is typically done is to use a bridging immunoassay format in which one batch of drug is conjugated to a biotin molecule and a separate batch of drug to a detector tag. These are then mixed together with a sample such that the ADA can form a bridge (thus, ‘bridging assay’) between the differently labeled drug — the biotin-drug is used to immobilize the biotin-drug/ADA/tag-drug complex to a solid surface, and the amount of ADA captured is measured by the detector signal.


In this month long feature, we bring you a collection of content focusing on the ‘hot topic’ of immuno-oncology.


Issue 20 of Bioanalysis volume 9 is now available, including an editorial surrounding the factors which may impact PK measurements of antibody therapeutics alongside the latest methodologies, research articles and discussions of current bioanalytical challenges. Find out more about the issue here, or on the Bioanalysis webpage.

Ask-the-experts-728x336.jpg new face

In this ‘Ask the Experts’ feature we will be discussing the use of biosimilars with a number of leading experts across the field. The series will explore the role of biosimilars, address the benefits and challenges of creating them and how they have gained momentum within the pharmaceutical industry.